ACEi/ARB Use Lowers Incidence of Appropriate ICD Shock

This article originally appeared here.
Share this content:
ACEi/ARB Use Lowers Incidence of Appropriate ICD Shock
ACEi/ARB Use Lowers Incidence of Appropriate ICD Shock

FRIDAY, April 10, 2015 (HealthDay News) -- For patients with cardiomyopathy, use of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) is associated with significantly lower incidence of appropriate implantable cardiac defibrillator (ICD) shocks, according to a study published in the April 1 issue of The American Journal of Cardiology.

Wael A. AlJaroudi, M.D., from the American University of Beirut Medical Center in Lebanon, and colleagues examined the role of ACEi or ARB use in preventing sudden cardiac death among patients with cardiomyopathy. Data were obtained for 1,509 patients, of whom 80 percent were on ACEi/ARB and 20 percent were not on ACEi/ARB. Five hundred seventy-four propensity-matched patients (287 in each group) were included in the analyses.

The researchers identified 334 appropriate implantable cardiac defibrillator shocks in the entire cohort over a mean of 2.5 years. At one, three, and five years, ACEi/ARB use correlated with lower incidence of shocks in the matched cohort (7.7, 16.7, and 18.5 versus 13.2, 27.5, and 32.0 percent, respectively; P = 0.005). Among patients with glomerular filtration rate (GFR) of >60 and 30 to 60 ml/min/1.73 m², the risk of ICD shock was increased by 45 and 77 percent, respectively, for those on no-ACEi/ARB versus those on ACEi/ARB.

"ACEi/ARB were associated with significant lower incidence of appropriate ICD shock in patients with cardiomyopathy and GFR ≥30 ml/min/1.73 m² and with neutral effect in those with GFR <30 ml/min/1.73 m²," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »